Peptides / Sexual health and hormones

Natural peptide · 54 amino acids · 5,798.4 Da

Kisspeptin-54 (metastin)

Not approvedBanned in sport

Kisspeptin-54 is the natural 54-amino-acid form of kisspeptin, the body's signal for the KISS1R receptor. It is not approved, and studies in people tested it in reproductive medicine, mainly on sex hormones and fertility. PepBank shows 142 results on kisspeptin-54 from 28 studies in people, and 139 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as KP-54, KP54, KISS-1, Kisspeptin, Kisspeptin-54, Metastin and 1 more

First 40 of 54 amino acids1 changed amino acid

Evidence level: Some studies in people142 of 281 results come from studies in people.

Results in people

142

51% of 281 results

Results in animals

102

36% of 281 results

Results in lab cells

13% of 281 results

From computer models

0% of 281 results

Overview

Kisspeptin-54 (metastin) at a glance

What it is	Natural peptide, 54 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2.2.1)
Studies	77 studies with results. 52 of them gave kisspeptin-54, with 281 results. 142 in people102 in animals37 in lab cells
Best study in people	Randomized controlled trial with 62 people (2017)
Clinical trials	1 registered: 0 active or planned, 1 with posted results
Community use	Restarting the body's own LH, FSH and testosterone after a steroid cycle (forum post that names KP-10 or KP-54); Research: triggering egg maturation in IVF in women at high risk of ovarian hyperstimulation; Research: brain and body responses to sexual stimuli in men with low sexual desire (HSDD); Research: nasal delivery to raise LH and FSH without an injection

The science

What is kisspeptin-54?

54-residue C-terminally amidated peptide from the KISS1 precursor; endogenous ligand of KISS1R. Studied in reproductive endocrinology; not an approved medicine.

Amino acids in one chain

The history of kisspeptin-54

2003
The oldest paper on kisspeptin-54 in PepBank is from 2003.
2012June
A registered trial of kisspeptin-54 started (NCT01667406).

Kisspeptin-54 (metastin) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 54 amino acidsFrom the first amino acid to the last

G1TSLS5PPP−ES10SGSPQ15QPGLS20APHS+R25QIPAP30QGAVL35VQ+R−E+K40−DLPNY45NWNSF50GL+RF

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Kisspeptin-54 (metastin) is a natural peptide of 54 amino acids, with no ring, 1 changed amino acid.

Formula

C₂₅₇H₃₉₆N₇₆O₇₈

Molecular weight

5,798.4 g/mol

CAS number

388138-21-4

Target

KiSS-1 receptor (gene KISS1R): agonistEvidence: primary literature

Development

No single developer. Sponsor of the kisspeptin-54 phase 2 study: Imperial College London (NCT01667406). Highest phase: phase 2.

Identifiers

PubChem 71306396, ChEMBL CHEMBL4650403, UNII 2VG74ZW2K5, IUPHAR 1288, UniProt Q15726

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Gly-Thr-Ser-Leu-Ser-Pro-Pro-Pro-Glu-Ser-Ser-Gly-Ser-Pro-Gln-Gln-Pro-Gly-Leu-Ser-Ala-Pro-His-Ser-Arg-Gln-Ile-Pro-Ala-Pro-Gln-Gly-Ala-Val-Leu-Val-Gln-Arg-Glu-Lys-Asp-Leu-Pro-Asn-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2

See charge, composition and 3D structure on the Scientific page

The evidence

What kisspeptin-54 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people142 of 281 results come from studies in people.

Sex hormones and fertility

167 results · 113 in people · 51 animal · 3 lab

In healthy adults, kisspeptin‑54 raised luteinizing hormone more than placebo. The Journal of clinical endocrinology and metabolism, 2025

Top results

In healthy adults, kisspeptin‑54 raised luteinizing hormone more than placebo. (The Journal of clinical endocrinology and metabolism, 2025)
In women at high risk of ovarian overstimulation, a second kisspeptin‑54 dose led to a good egg yield in more women than one dose. (Human reproduction, 2017)
In healthy men, kisspeptin sprayed into the nose raised luteinising hormone more than saline, and a higher dose gave a larger rise. (Journal of the Endocrine Society, 2022)

Sexual and women's health

8 results · 8 in people

In women with low sexual desire, kisspeptin changed activity in the left inferior frontal gyrus during sexual and attractiveness tasks compared with placebo. JAMA network open, 2022

Top results

In women with low sexual desire, kisspeptin changed activity in the left inferior frontal gyrus during sexual and attractiveness tasks compared with placebo. (JAMA network open, 2022)
In men with low sexual desire, kisspeptin‑54 raised penile response to sexual stimuli more than placebo did. (JAMA network open, 2023)
In women with low sexual desire, kisspeptin increased activity in the right postcentral and supramarginal gyrus during sexual and attractiveness tasks compared with placebo. (JAMA network open, 2022)

Heart and blood vessels

7 results · 5 in people · 2 lab

In healthy adults, kisspeptin‑54 did not change systolic blood pressure compared with placebo. The Journal of clinical endocrinology and metabolism, 2025

Top results

In healthy adults, kisspeptin‑54 did not change systolic blood pressure compared with placebo. (The Journal of clinical endocrinology and metabolism, 2025)
In healthy adults, kisspeptin‑54 did not change heart rate compared with placebo. (The Journal of clinical endocrinology and metabolism, 2025)
In lab tests on human artery rings, kisspeptin‑54 made the vessel tissue contract. (Endocrinology, 2007)

Growth hormone and growth

4 results · 4 in people

In healthy women, growth hormone did not change in the first hours after kisspeptin‑54 compared with vehicle. Clinical endocrinology, 2014

Top results

In healthy women, growth hormone did not change in the first hours after kisspeptin‑54 compared with vehicle. (Clinical endocrinology, 2014)
In healthy women, how often growth hormone pulses occurred did not change after kisspeptin‑54 compared with vehicle. (Clinical endocrinology, 2014)
In healthy women, the size of growth hormone pulses did not change after kisspeptin‑54 compared with vehicle. (Clinical endocrinology, 2014)

Hormones

4 results · 4 in people

In healthy women, prolactin did not change in the first hours after kisspeptin‑54 compared with vehicle. Clinical endocrinology, 2014

Top results

In healthy women, prolactin did not change in the first hours after kisspeptin‑54 compared with vehicle. (Clinical endocrinology, 2014)
In healthy women, TSH did not change in the first hours after kisspeptin‑54 compared with vehicle. (Clinical endocrinology, 2014)
In healthy women, a week of kisspeptin‑54 injections did not change prolactin compared with vehicle. (Clinical endocrinology, 2014)

Mood, stress and behavior

4 results · 2 in people · 2 animal

In healthy adults, kisspeptin‑54 did not change anxiety scores compared with placebo. The Journal of clinical endocrinology and metabolism, 2025

Top results

In healthy adults, kisspeptin‑54 did not change anxiety scores compared with placebo. (The Journal of clinical endocrinology and metabolism, 2025)
In healthy adults, kisspeptin‑54 did not change cortisol compared with placebo. (The Journal of clinical endocrinology and metabolism, 2025)
In rats with a Parkinson-like lesion, nasal kisspeptin‑54 reduced depression-like behavior. (Balkan medical journal, 2024)

All 77 kisspeptin-54 studies by area Open the Scientific page

Key kisspeptin-54 studies

Studies in people come first, then studies in animals and in the lab.

People
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial
Abbara et al. 2017 · Human reproduction (Oxford, England) · 62 people · cited by 49
4 results
People
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy
Abbara et al. 2015 · The Journal of clinical endocrinology and metabolism · 60 people · cited by 101
10 results
People
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Thurston et al. 2022 · JAMA network open · 32 people · cited by 27
6 results
People
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Mills et al. 2023 · JAMA network open · 32 people · cited by 24
3 results
People
Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans
Mills et al. 2025 · The Journal of clinical endocrinology and metabolism · 95 people · cited by 2
6 results

All 77 Kisspeptin-54 (metastin) studies

Kisspeptin-54 clinical trials

ClinicalTrials.gov lists 1 trial of kisspeptin-54. 0 are active or planned, and 1 has posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Phase 2completed175 people

Status and safety

Is kisspeptin-54 approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.1.

No. Not approved for any use. Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 13 Oct 2026). Banned in sport (WADA S2.2.1).

Laws and labels change, so check the regulator for the current status.

Kisspeptin-54 side effects and safety

PepBank has 19 safety results from studies of kisspeptin-54. 9 of them come from studies in people.

Safety results from studies (19)

In women at high risk of ovarian overstimulation, a second kisspeptin‑54 dose did not raise rates of overstimulation compared with one dose. (Human reproduction, 2017)
In women at high risk of ovarian overstimulation having IVF, no woman developed moderate, severe or critical overstimulation after kisspeptin‑54. (The Journal of clinical endocrinology and metabolism, 2015)
In women with hypothalamic amenorrhea, researchers saw no side effects with kisspeptin‑54. (Clinical pharmacology and therapeutics, 2010)
In women with low sexual desire, kisspeptin infusion was well tolerated and no adverse effects were reported. (JAMA network open, 2022)
In healthy adults and women with hypothalamic amenorrhoea, nasal kisspeptin‑54 caused no side effects or adverse events. (EBioMedicine, 2025)
In women having IVF, markers linked to ovarian overstimulation did not change after kisspeptin‑54. (Human reproduction, 2018)
In healthy men and women, kisspeptin‑54 was not linked to changes in blood pressure. (British journal of clinical pharmacology, 2010)
In women at high risk of ovarian overstimulation having IVF, two kisspeptin‑54 injections did not raise overstimulation rates compared with one. (Imperial College London, 2018)
In healthy men and women, kisspeptin‑54 was not linked to changes in heart rate. (British journal of clinical pharmacology, 2010)
In rats, 13 days of continuous kisspeptin‑54 lowered testis weight. (American journal of physiology. Endocrinology and metabolism, 2006)
In male rats, continuous kisspeptin‑54 under the skin damaged the testes within 12 hours. (British journal of pharmacology, 2009)
In healthy mice, kisspeptin‑54 alone at therapeutic doses was not toxic. (Neuropeptides, 2026)
In rats, 13 days of continuous kisspeptin‑54 damaged the tubules in the testis where sperm form. (American journal of physiology. Endocrinology and metabolism, 2006)
In rats, 13 days of continuous kisspeptin‑54 lowered a hormone made by the testes. (American journal of physiology. Endocrinology and metabolism, 2006)
In rats, free testosterone was lower after 13 days of continuous kisspeptin‑54, but the difference was not statistically significant. (American journal of physiology. Endocrinology and metabolism, 2006)
In rats, total testosterone was lower after 13 days of continuous kisspeptin‑54, but the difference was not statistically significant. (American journal of physiology. Endocrinology and metabolism, 2006)
In male rats, one kisspeptin‑54 injection under the skin damaged the testes, and more peptide caused more damage. (British journal of pharmacology, 2009)
In male rats, kisspeptin‑54 injected into the brain also damaged the testes. (British journal of pharmacology, 2009)
In cells in the lab, kisspeptin‑54 did not directly change genes linked to ovarian overstimulation. (Human reproduction, 2018)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
9.6 nmol/kg first dose, second dose 10 h later	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 62	Abbara 2017
3.2, 6.4, 9.6 or 12.8 nmol/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 60	Abbara 2015
1 nmol/kg/h	Human	human	intravenous	75 minutes	Randomized trial in people · n = 32	Thurston 2022
1 nmol/kg/h	Human	human	intravenous infusion	75 minutes	Randomized trial in people · n = 32	Mills 2023
1 nmol/kg/h	Human	human	intravenous	75 minutes	Randomized trial in people · n = 95	Mills 2025
12.8 nmol/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 25	Abbara 2015
3.2-12.8 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people · n = 12	2022
3.2 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people · n = 12	2022
6.4 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people · n = 12	2022
12.8 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people · n = 12	2022
25.6 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people · n = 12	2022
0.4 nmol/kg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 8	Dhillo 2007
4 pmol/kg x min	Human	human	intravenous infusion	90 min	Randomized trial in people · n = 6	Dhillo 2005
6.4 nmol/kg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 5	Jayasena 2009
9.6 nmol/kg	Human	human	Not reported	Not reported	Randomized trial in people	Abbara 2015
12.8 nmol/kg	Human	human	intranasal	Not reported	Randomized trial in people	Mills 2025
1.6-12.8 nmol/kg	Human	human	subcutaneous	single injection	Trial in people without random groups · n = 53	Jayasena 2014
1.6, 3.2, 6.4 or 12.8 nmol/kg	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 53	Christopoulos 2015
6.4 nmol/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 42	Abbara 2021
6.4-12.8 nmol/kg	Human	human	subcutaneous	21 days	Trial in people without random groups · n = 12	Romero-Ruiz 2019
0.1, 0.3, or 1.0 nmol/kg/h	Human	human	intravenous	3 hours	Trial in people without random groups · n = 10	Abbara 2018
1.0 nmol/kg/h	Human	human	intravenous	3 hours	Trial in people without random groups · n = 10	Abbara 2018
9.6 nmol/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 9	Abbara 2020
0·30 nmol/kg	Human	human	subcutaneous	single injection	Trial in people without random groups · n = 6	Jayasena 2013
0·60 nmol/kg	Human	human	subcutaneous	single injection	Trial in people without random groups · n = 6	Jayasena 2013
0.01-1.00 nmol/kg/h	Human	human	intravenous infusion	Not reported	Trial in people without random groups · n = 5	Jayasena 2014
1.0 nmol/kg/h	Human	human	intravenous	3 h infusion	Trial in people without random groups · n = 5	Jayasena 2015
0.1, 0.3 and 1.0 nmol/kg/h	Human	human	intravenous	3 h infusion	Trial in people without random groups · n = 5	Jayasena 2015
6.4 nmol/kg twice daily	Human	human	subcutaneous	menstrual days 7-14	Trial in people without random groups · n = 5	Jayasena 2013
6·4 nmol/kg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 5	Jayasena 2014
0·1, 0·3 or 1·0 nmol/kg/h	Human	human	subcutaneous infusion	8 h	Trial in people without random groups · n = 4	Narayanaswamy 2016
0·3 and 1·0 nmol/kg/h	Human	human	subcutaneous infusion	8 h	Trial in people without random groups · n = 4	Narayanaswamy 2016
1·0 nmol/kg/h	Human	human	subcutaneous infusion	8 h	Trial in people without random groups · n = 4	Narayanaswamy 2016
0.2-6.4 nmol/kg	Human	human	subcutaneous	Not reported	Trial in people without random groups	Dhillo 2007
9.6 nmol/kg, one injection or two injections 10 h apart	Human	human	Not reported	Not reported	Trial in people without random groups	Owens 2018
6.4 nmol/kg	Human	human	injection	two weeks	Other study type	Nijher 2012
100 μg/kg	Animal	rat	subcutaneous	11 days	Study in live animals · n = 10	Romero-Ruiz 2019
3 nmol	Animal	mouse	Not reported	Not reported	Study in live animals · n = 10	Abdelkareem 2023
as low as 1 fmol	Animal	mouse	intracerebroventricular	Not reported	Study in live animals	Gottsch 2004
0.02, 0.2 and 2 nmol	Animal	rat	third ventricle injection	Not reported	Study in live animals	Yamada 2007

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Almost all community talk about kisspeptin does not say which form it means, and the form people most often report is kisspeptin-10. One bodybuilding forum post names 'KP-10 or KP-54' together at 100 to 200 mcg under the skin for hormone recovery after a steroid cycle. Kisspeptin-54 doses with a clear source come from human trial papers. They are weight-based (nmol/kg) and were given under medical supervision.

Reported routines and cautions

What people use it for

Restarting the body's own LH, FSH and testosterone after a steroid cycle (forum post that names KP-10 or KP-54)S1
Research: triggering egg maturation in IVF in women at high risk of ovarian hyperstimulationS5 S6
Research: brain and body responses to sexual stimuli in men with low sexual desire (HSDD)S4
Research: nasal delivery to raise LH and FSH without an injectionS8

Reported regimens

Regimens that community sources report for Kisspeptin-54. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Hormone recovery after a steroid cycle. The forum post names 'KP-10 or KP-54' together, so the amount is not specific to kisspeptin-54.	subcutaneous injection	100 to 200 mcg per dose	once or twice daily	about 4 to 6 weeks	single source (one forum post). The post does not separate KP-10 and KP-54, so the amount is not specific to kisspeptin-54	S1
Research setting, trial dosing reported in a paper: single dose to trigger egg maturation in IVF, women at high risk of ovarian hyperstimulation syndrome (OHSS)	subcutaneous injectiongiven about 36 hours before egg retrieval	9.6 nmol/kg per dose	single dose (a second dose 10 hours later was tested in half of the women)	Not stated	2 trials by the same group. S5 gave 9.6 nmol/kg to all 62 women. S6 tested 3.2 to 12.8 nmol/kg. They are not independent	S5 S6
Research setting, trial dosing reported in a paper: repeated injections in healthy women over one week (5 women, each had a saline cycle and a kisspeptin cycle)	subcutaneous injection	6.4 nmol/kg per dose	twice daily	7 days (menstrual days 7 to 14)	single source	S7
Research setting, trial dosing reported in a paper: one infusion per study visit in men with low sexual desire (HSDD), with brain scanning	intravenous infusion	1 nmol/kg per hour	single infusion per visit	75 minutes	trial paper (S4). S2 repeats the trial dose and may copy it from the paper, so the two sources are not independent	S4S2
Research setting, trial dosing reported in a paper: intranasal kisspeptin-54 in healthy volunteers and patients with hypothalamic amenorrhea	intranasalself-administered nasal spray in the trial	12.8 nmol/kg per dose	single dose per study visit	Not stated	single source	S8

Reported side effects

no adverse events or side effects reported in the 75-minute infusion trial in men with low sexual desire (trial paper and a forum guide)S4S2
a shorter mean menstrual cycle (26.8 days vs 28.6 days on saline) after one week of twice-daily injections in 5 healthy womenS7

Reported benefits (claims, not shown in trials)

restart of the body's own GnRH pulses, LH, FSH and testosterone after a steroid cycle (a forum author's claim, no personal data given)S1
in IVF, a second dose 10 hours after the first improved egg yield in women at high risk of OHSS (phase 2 trial)S5
in men with low sexual desire, brain activity in sexual-processing areas changed compared with placebo (trial, intravenous infusion)S4
intranasal kisspeptin-54 raised LH in trial groups, with no side effects or adverse events reported in the paperS8

Cautions

The only community post found that names kisspeptin-54 also names KP-10 in the same line. A forum guide says the most common community-reported dose is KP-10. Community amounts in mcg cannot be tied to kisspeptin-54 alone.S1S2
Trial doses are weight-based (nmol/kg) and were given in studies under medical supervision. In the 1-week injection trial the women injected themselves, and in the nasal trial the volunteers used the spray under supervision. A forum guide says extrapolating trial results directly to community protocols requires caution.S2S5 S7 S4 S8
Daily kisspeptin-54 infusion in women is reported to cause receptor desensitization and LH suppression. A forum guide says many researchers recommend against daily use. The twice-daily trial for one week did not stop menstrual cycles in 5 women.S2S7
Products sourced from research peptide suppliers carry uncertainty about purity, dose accuracy and sterility.S2
A wiki says the effects of chronic kisspeptin use on the HPG axis are less well characterized and may differ from the acute responses seen in studies.S3

Status notes

Kisspeptin-54 is not an FDA-approved medicine. FDA's compounding category list names kisspeptin-10 (503A category 2) and does not name kisspeptin-54, so it is in no 503A or 503B category. A forum guide says US compounding pharmacies cannot legally prepare kisspeptin.S10S2
WADA 2026 Prohibited List S2.2.1 (testosterone-stimulating peptides in males) names 'kisspeptin and its agonist analogues'. The 2027 List carries the same text.S9 S11

Community sources

S1Using Kisspeptin Peptides for Advanced HPTA Reactivationmusclemecca.comcarries seller links, not linked
S2Kisspeptin Peptide Practical Guideexcelmale.comcarries seller links, not linked
S3Kisspeptin: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S4Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (opens in a new tab)pmc.ncbi.nlm.nih.gov
S5A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial (opens in a new tab)pmc.ncbi.nlm.nih.gov
S6Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy (opens in a new tab)pmc.ncbi.nlm.nih.gov
S7Twice-Daily Subcutaneous Injection of Kisspeptin-54 Does Not Abolish Menstrual Cyclicity in Healthy Female Volunteers (opens in a new tab)pmc.ncbi.nlm.nih.gov
S8Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans (opens in a new tab)pmc.ncbi.nlm.nih.gov
S9World Anti-Doping Agency 2026 Prohibited List (opens in a new tab)wada-ama.org
S10FDA: Bulk drug substances nominated for use in compounding under section 503A (categories) (opens in a new tab)fda.gov
S11World Anti-Doping Agency 2027 Prohibited List (opens in a new tab)wada-ama.org

Gaps

No first-hand report that names kisspeptin-54 was found. Community talk says 'kisspeptin' or kisspeptin-10. The Peptide Protocol Wiki page (S3) is titled 'Kisspeptin (Kisspeptin-10)', so its 100 to 200 mcg protocols were not used for this record. The candidate YouTube Short (Anabolic Network, 'Testosterone at 150. Told to Stop TRT. Ran Kisspeptin') cannot be quoted from a script and does not name the form in its title, so it was not used. The only community post that names KP-54 (S1) is a single bodybuilding forum article with one reply; its reply asks about KP-10. S1 carries banner ads for steroid shops. S2 links to a lab-test affiliate and a peptide directory. S3 carries supplier rankings. The Peptide Protocol Wiki dosing page (a trial summary) was left out in favour of the trial papers. A database page (peptide-db.com) lists '0.4-1.0 nmol/kg (50-150mcg) ... SubQ (KP-54)' for fertility support but gives no trial source, so it was not used. Trial doses are for supervised clinic use. No harm-reduction page or regulator page for self-use was found. Reddit was not used. The PubMed pages return HTTP 203 to scripts, so quotes were checked on PMC full text.

Questions and more

Ask a question about kisspeptin-54

The answer links to every study it uses.

What does the evidence say about kisspeptin-54?Is kisspeptin-54 tested in people?Compare with Oxytocin Compare with Kisspeptin-10

Sources

Database: PepBank data for kisspeptin-54 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about kisspeptin-54

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Kisspeptin-54 (metastin)

Not approvedBanned in sport

Also known as KP-54, KP54, KISS-1, Kisspeptin, Kisspeptin-54, Metastin and 1 more

What it is

Natural peptide, 54 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2.2.1)

Studies

77 studies with results. 52 of them gave kisspeptin-54, with 281 results.
142 in people102 in animals37 in lab cells

Best study in people

Randomized controlled trial with 62 people (2017)

Clinical trials

1 registered: 0 active or planned, 1 with posted results

Community use

Restarting the body's own LH, FSH and testosterone after a steroid cycle (forum post that names KP-10 or KP-54); Research: triggering egg maturation in IVF in women at high risk of ovarian hyperstimulation; Research: brain and body responses to sexual stimuli in men with low sexual desire (HSDD); Research: nasal delivery to raise LH and FSH without an injection

Dose as reported

Class

Species

Route

Duration

Design

Source

9.6 nmol/kg first dose, second dose 10 h later

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 62

Abbara 2017

3.2, 6.4, 9.6 or 12.8 nmol/kg

Human

human

Not reported

Randomized trial in people · n = 60

Abbara 2015

1 nmol/kg/h

Human

human

intravenous

75 minutes

Randomized trial in people · n = 32

Thurston 2022

1 nmol/kg/h

Human

human

intravenous infusion

75 minutes

Randomized trial in people · n = 32

Mills 2023

1 nmol/kg/h

Human

human

intravenous

75 minutes

Randomized trial in people · n = 95

Mills 2025

12.8 nmol/kg

Human

human

Not reported

Randomized trial in people · n = 25

Abbara 2015

3.2-12.8 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people · n = 12

2022

3.2 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people · n = 12

2022

6.4 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people · n = 12

2022

12.8 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people · n = 12

2022

25.6 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people · n = 12

2022

0.4 nmol/kg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 8

Dhillo 2007

4 pmol/kg x min

Human

human

intravenous infusion

90 min

Randomized trial in people · n = 6

Dhillo 2005

6.4 nmol/kg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 5

Jayasena 2009

9.6 nmol/kg

Human

human

Not reported

Randomized trial in people

Abbara 2015

12.8 nmol/kg

Human

human

intranasal

Not reported

Randomized trial in people

Mills 2025

1.6-12.8 nmol/kg

Human

human

subcutaneous

single injection

Trial in people without random groups · n = 53

Jayasena 2014

1.6, 3.2, 6.4 or 12.8 nmol/kg

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 53

Christopoulos 2015

6.4 nmol/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 42

Abbara 2021

6.4-12.8 nmol/kg

Human

human

subcutaneous

21 days

Trial in people without random groups · n = 12

Romero-Ruiz 2019

0.1, 0.3, or 1.0 nmol/kg/h

Human

human

intravenous

3 hours

Trial in people without random groups · n = 10

Abbara 2018

1.0 nmol/kg/h

Human

human

intravenous

3 hours

Trial in people without random groups · n = 10

Abbara 2018

9.6 nmol/kg

Human

human

Not reported

Trial in people without random groups · n = 9

Abbara 2020

0·30 nmol/kg

Human

human

subcutaneous

single injection

Trial in people without random groups · n = 6

Jayasena 2013

0·60 nmol/kg

Human

human

subcutaneous

single injection

Trial in people without random groups · n = 6

Jayasena 2013

0.01-1.00 nmol/kg/h

Human

human

intravenous infusion

Not reported

Trial in people without random groups · n = 5

Jayasena 2014

1.0 nmol/kg/h

Human

human

intravenous

3 h infusion

Trial in people without random groups · n = 5

Jayasena 2015

0.1, 0.3 and 1.0 nmol/kg/h

Human

human

intravenous

3 h infusion

Trial in people without random groups · n = 5

Jayasena 2015

6.4 nmol/kg twice daily

Human

human

subcutaneous

menstrual days 7-14

Trial in people without random groups · n = 5

Jayasena 2013

6·4 nmol/kg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 5

Jayasena 2014

0·1, 0·3 or 1·0 nmol/kg/h

Human

human

subcutaneous infusion

8 h

Trial in people without random groups · n = 4

Narayanaswamy 2016

0·3 and 1·0 nmol/kg/h

Human

human

subcutaneous infusion

8 h

Trial in people without random groups · n = 4

Narayanaswamy 2016

1·0 nmol/kg/h

Human

human

subcutaneous infusion

8 h

Trial in people without random groups · n = 4

Narayanaswamy 2016

0.2-6.4 nmol/kg

Human

human

subcutaneous

Not reported

Trial in people without random groups

Dhillo 2007

9.6 nmol/kg, one injection or two injections 10 h apart

Human

human

Not reported

Trial in people without random groups

Owens 2018

6.4 nmol/kg

Human

human

injection

two weeks

Other study type

Nijher 2012

100 μg/kg

Animal

rat

subcutaneous

11 days

Study in live animals · n = 10

Romero-Ruiz 2019

3 nmol

Animal

mouse

Not reported

Study in live animals · n = 10

Abdelkareem 2023

as low as 1 fmol

Animal

mouse

intracerebroventricular

Not reported

Study in live animals

Gottsch 2004

0.02, 0.2 and 2 nmol

Animal

rat

third ventricle injection

Not reported

Study in live animals

Yamada 2007

Context

Route

Amount

How often

How long

Agreement

Sources

Hormone recovery after a steroid cycle. The forum post names 'KP-10 or KP-54' together, so the amount is not specific to kisspeptin-54.

subcutaneous injection

100 to 200 mcg per dose

once or twice daily

about 4 to 6 weeks

single source (one forum post). The post does not separate KP-10 and KP-54, so the amount is not specific to kisspeptin-54

Research setting, trial dosing reported in a paper: single dose to trigger egg maturation in IVF, women at high risk of ovarian hyperstimulation syndrome (OHSS)

subcutaneous injectiongiven about 36 hours before egg retrieval

9.6 nmol/kg per dose

single dose (a second dose 10 hours later was tested in half of the women)

Not stated

2 trials by the same group. S5 gave 9.6 nmol/kg to all 62 women. S6 tested 3.2 to 12.8 nmol/kg. They are not independent

S5 S6

Research setting, trial dosing reported in a paper: repeated injections in healthy women over one week (5 women, each had a saline cycle and a kisspeptin cycle)

subcutaneous injection

6.4 nmol/kg per dose

twice daily

7 days (menstrual days 7 to 14)

single source

Research setting, trial dosing reported in a paper: one infusion per study visit in men with low sexual desire (HSDD), with brain scanning

intravenous infusion

1 nmol/kg per hour

single infusion per visit

75 minutes

trial paper (S4). S2 repeats the trial dose and may copy it from the paper, so the two sources are not independent

S4S2

Research setting, trial dosing reported in a paper: intranasal kisspeptin-54 in healthy volunteers and patients with hypothalamic amenorrhea

intranasalself-administered nasal spray in the trial

12.8 nmol/kg per dose

single dose per study visit

Not stated

single source

Kisspeptin-54 (metastin)

Kisspeptin-54 (metastin) at a glance

What is kisspeptin-54?

The history of kisspeptin-54

Kisspeptin-54 (metastin) structure and chemistry

What kisspeptin-54 studies show

Sex hormones and fertility

Sexual and women's health

Heart and blood vessels

Growth hormone and growth

Hormones

Mood, stress and behavior

Key kisspeptin-54 studies

Kisspeptin-54 clinical trials

Is kisspeptin-54 approved?

Kisspeptin-54 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about kisspeptin-54

Related peptides

Sources

Kisspeptin-54 (metastin)

Kisspeptin-54 (metastin) at a glance

What is kisspeptin-54?

The history of kisspeptin-54

Kisspeptin-54 (metastin) structure and chemistry

What kisspeptin-54 studies show

Sex hormones and fertility

Sexual and women's health

Heart and blood vessels

Growth hormone and growth

Hormones

Mood, stress and behavior

Key kisspeptin-54 studies

Kisspeptin-54 clinical trials

Is kisspeptin-54 approved?

Kisspeptin-54 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about kisspeptin-54

Related peptides

Sources